Alan Kaneshige, MD
Cardiovascular Disease · Tulsa, OKNPI 1710957535
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,960 of the $10,809 with a category attached, or 82.9%. Novartis accounts for 86.6% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $9,493 and has fallen 98.4% since, to $152 in 2025.
Across 73 payments — averaging $148.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$9K
- Abiomed$368
- E.r. Squibb & Sons, L.L.C.$197
- Lexicon Pharmaceuticals, Inc.$115
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$111
- Johnson & Johnson$108
- plus $548 from 14 others
Across 15 payments — averaging $2354.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$35K
- Amgen$82
What the payments were for
- Speaking & faculty fees$8,96083%
- Food & beverage$1,84917%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $9,362 |
| Abiomed | 3 | $368 |
| E.r. Squibb & Sons, L.L.C. | 12 | $197 |
| Lexicon Pharmaceuticals, Inc. | 1 | $115 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $111 |
| Johnson & Johnson | 7 | $108 |
| Boston Scientific | 3 | $87 |
| Amgen | 5 | $84 |
| Actelion Pharmaceuticals US, Inc. | 4 | $76 |
| Merck | 4 | $64 |
| Lantheus Medical Imaging, Inc. | 3 | $51 |
| AstraZeneca | 2 | $38 |
| Abbott | 2 | $36 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Surmodics, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Gilead | 1 | $13 |
| Edwards Lifesciences | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,809 in reported general payments places this provider in the 85th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 233 | $205,449 |
| EntrestoSacubitril/Valsartan | 157 | $159,820 |
| JardianceEmpagliflozin | 100 | $78,898 |
| XareltoRivaroxaban | 70 | $73,613 |
| Repatha SureclickEvolocumab | 33 | $27,423 |
| FarxigaDapagliflozin Propanediol | 19 | $25,078 |
| VascepaIcosapent Ethyl | 18 | $8,820 |
| Ezetimibe | 250 | $6,352 |
| Rosuvastatin Calcium | 366 | $4,983 |
| Metoprolol Succinate | 305 | $4,546 |
| Atorvastatin Calcium | 266 | $3,791 |
| Nebivolol Hcl | 38 | $3,066 |
| Omega-3 Acid Ethyl Esters | 45 | $2,346 |
| Ranolazine ErRanolazine | 31 | $2,136 |
| Amlodipine Besylate | 216 | $1,939 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $9,362 | $159,820157 claims |
| Johnson & JohnsonXarelto | $108 | $73,61370 claims |
| AstraZenecaFarxiga | $38 | $25,07819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Tulsa
- Frank GaffneyTulsa$211K
- Mohamad KhattabTulsa$47K
- Steve KimTulsa$38K
- Eric AuerbachTulsa$35K
- David WilkettTulsa$25K
- Daniel WildesTulsa$24K
- Thomas KalapuraTulsa$17K
- Heather ChaTulsa$16K
- Christopher HigginsTulsa$13K
- Neil AgrawalTulsa$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.